SARS-CoV-2 variants: levels of neutralisation required for protective immunity
View ORCID ProfileDeborah Cromer, View ORCID ProfileMegan Steain, View ORCID ProfileArnold Reynaldi, View ORCID ProfileTimothy E Schlub, View ORCID ProfileAdam K Wheatley, View ORCID ProfileJennifer A Juno, View ORCID ProfileStephen J Kent, View ORCID ProfileJames A Triccas, View ORCID ProfileDavid S Khoury, View ORCID ProfileMiles P Davenport
doi: https://doi.org/10.1101/2021.08.11.21261876
Deborah Cromer
1Kirby Institute, University of New South Wales, Sydney, Australia
Megan Steain
2Sydney Institute of Infectious Diseases and Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
3School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Arnold Reynaldi
1Kirby Institute, University of New South Wales, Sydney, Australia
Timothy E Schlub
1Kirby Institute, University of New South Wales, Sydney, Australia
4Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
Adam K Wheatley
5Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
Jennifer A Juno
5Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
Stephen J Kent
5Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
6Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia
James A Triccas
3School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
2Sydney Institute of Infectious Diseases and Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
David S Khoury
1Kirby Institute, University of New South Wales, Sydney, Australia
Miles P Davenport
1Kirby Institute, University of New South Wales, Sydney, Australia
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted August 13, 2021.
SARS-CoV-2 variants: levels of neutralisation required for protective immunity
Deborah Cromer, Megan Steain, Arnold Reynaldi, Timothy E Schlub, Adam K Wheatley, Jennifer A Juno, Stephen J Kent, James A Triccas, David S Khoury, Miles P Davenport
medRxiv 2021.08.11.21261876; doi: https://doi.org/10.1101/2021.08.11.21261876
SARS-CoV-2 variants: levels of neutralisation required for protective immunity
Deborah Cromer, Megan Steain, Arnold Reynaldi, Timothy E Schlub, Adam K Wheatley, Jennifer A Juno, Stephen J Kent, James A Triccas, David S Khoury, Miles P Davenport
medRxiv 2021.08.11.21261876; doi: https://doi.org/10.1101/2021.08.11.21261876
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2661)
- Dermatology (224)
- Emergency Medicine (402)
- Epidemiology (12264)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4122)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2670)
- Health Policy (1008)
- Hematology (364)
- HIV/AIDS (855)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (442)
- Neurology (3912)
- Nursing (210)
- Nutrition (582)
- Oncology (2048)
- Ophthalmology (587)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (455)
- Public and Global Health (6551)
- Radiology and Imaging (1410)
- Respiratory Medicine (872)
- Rheumatology (412)
- Sports Medicine (344)
- Surgery (452)
- Toxicology (54)
- Transplantation (186)
- Urology (167)